Xinbang Pharmaceuticals: Report for the third quarter of 2024

SZSIOct 31 00:00 · Announcements

Guizhou Xinbang Pharmaceutical (002390.SZ): The net income for the first three quarters was 0.177 billion yuan, a 28.38% year-on-year decrease.

Guizhou Xinbang Pharmaceutical (002390.SZ) announced its third quarter report for 2024 on October 30. In the first three quarters of 2024, the company achieved revenue of 4.565 billion yuan, a decrease of 5.35% year-on-year; net income attributable to shareholders of the listed company was 0.177 billion yuan, a decrease of 28.38% year-on-year; net income after deducting non-recurring gains and losses was 0.175 billion yuan, a decrease of 29.08% year-on-year; basic earnings per share were 0.0927 yuan per share.

Gelonghui FinanceOct 30 17:43

Guizhou Xinbang Pharmaceutical (002390.SZ): Its hospital offers testing services such as lymphocyte subgroups, lymphocyte activation, dendritic cells, cell apoptosis, and leukemia immune analysis.

Guizhou Xinbang Pharmaceutical (002390.SZ) stated on the investor interaction platform that its hospitals have testing services for lymphocyte subsets, lymphocyte activation, dendritic cells, cell apoptosis, and leukemia immunological analysis.

Gelonghui FinanceSep 20 15:45

Guizhou Xinbang Pharmaceutical (002390.SZ): The produced Yixinshu capsules, Maixuekang capsules, silver ginkgo biloba leaves, and Lamp Plant Extract are suitable for the middle-aged and elderly population.

On September 19, Guizhou Xinbang Pharmaceutical (002390.SZ) stated on the investor interaction platform that the company's products such as Yixinshu capsules, Maixuekang capsules, silver ginkgo biloba leaves, and dendrobium extract are suitable for the middle-aged and elderly. As a leading pharmaceutical distribution company in Guizhou Province, the company has established a comprehensive distribution system including pharmaceuticals and medical devices. The drugs sold by the company's subsidiary pharmaceutical distribution company include the categories you are concerned about. Currently, the affiliated Baiyun Hospital of Guizhou Medical University under the company has set up sanatorium wards in the general medical department, providing professional treatment and care for elderly patients.

Gelonghui FinanceSep 19 17:36

Guizhou Xinbang Pharmaceutical (002390): Short-term pressure on medical services, rapid release of traditional Chinese medicine granules

Key investment points: Short-term pressure on performance, declining profitability. In H1 2024, the company achieved revenue of 3.047 billion yuan, a decrease of 6.45%; net income attributable to shareholders was 0.115 billion yuan, a year-on-year decrease of 26.37%; net cash flow from operating activities

東海證券Sep 5 00:00

Xinbang Pharmaceuticals: 2024 Semi-Annual Report Summary

SZSIAug 31 00:00 · Announcements